Looking At Iovance Biotherapeutics's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Iovance Biotherapeutics IOVA.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IOVA, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 14 uncommon options trades for Iovance Biotherapeutics.

This isn't normal.

The overall sentiment of these big-money traders is split between 42% bullish and 50%, bearish.

Out of all of the special options we uncovered, 6 are puts, for a total amount of $167,238, and 8 are calls, for a total amount of $525,900.

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.5 to $11.0 for Iovance Biotherapeutics over the last 3 months.

Volume & Open Interest Trends

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Iovance Biotherapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Iovance Biotherapeutics's significant trades, within a strike price range of $7.5 to $11.0, over the past month.

Iovance Biotherapeutics 30-Day Option Volume & Interest Snapshot

Largest Options Trades Observed:

About Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Following our analysis of the options activities associated with Iovance Biotherapeutics, we pivot to a closer look at the company's own performance.

Current Position of Iovance Biotherapeutics

• With a volume of 9,592,848, the price of IOVA is down -4.79% at $8.46.
• RSI indicators hint that the underlying stock may be oversold.
• Next earnings are expected to be released in 64 days.

What The Experts Say On Iovance Biotherapeutics

In the last month, 4 experts released ratings on this stock with an average target price of $32.0.

• An analyst from HC Wainwright & Co. has revised its rating downward to Buy, adjusting the price target to $32.
• An analyst from HC Wainwright & Co. downgraded its action to Buy with a price target of $32.
• Reflecting concerns, an analyst from HC Wainwright & Co. lowers its rating to Buy with a new price target of $32.
• An analyst from HC Wainwright & Co. downgraded its action to Buy with a price target of $32.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Iovance Biotherapeutics options trades with real-time alerts from Benzinga Pro.